Market News & Trends
Clearmind Medicine Advances Fight Against Cocaine Addiction With Publication of US Patent Application for its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Clearmind Medicine Inc. recently announced the publication of a US patent application expanding coverage of its non-hallucinogenic proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of…
Zag Bio Launches With $80 Million Financing to Advance Thymus-Targeted Medicines for Autoimmune Diseases
Zag Bio, Inc. recently announced the company’s launch with $80 million in financing, including a recently closed Series A financing. Polaris Partners founded and incubated Zag…
Slingshot Biosciences & Cellares Combine TruCytes Biomarker Controls With Cell Q Platform to Enhance Quality & Automation in Cell Therapy Manufacturing
Slingshot Biosciences recently announced a strategic collaboration with Cellares that integrates Slingshot’s TruCytes Biomarker controls into Cellares’ Cell Q, the industry’s first fully automated quality-control…
Olympia Pharmaceuticals Strengthens National Presence, Bringing New Licensing to Mississippi
Olympia Pharmaceuticals recently announced its expansion into Mississippi after successfully obtaining licensing in the state. This is a significant step in its goal to support…
Zenas BioPharma Announces Positive Results From Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Zenas BioPharma, Inc. recently announced positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS). Obexelimab met the primary endpoint,…
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today presented new preclinical data…
NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination With a GLP-1 Receptor Agonist
NodThera, a clinical-stage biotech pioneering a paradigm shift in the treatment of chronic inflammatory diseases through NLRP3 inhibition, today announced that the first patients have…
Curia Invests $4 Million to Enhance Sterile API Manufacturing
Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of a $4 million investment to upgrade its two…
Thermo Fisher Scientific Showcases Enhanced Accelerator Drug Development Capabilities & OpenAI Strategic Collaboration at CPHI Frankfurt 2025
Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest flexible solutions to help boost efficiency and scale in biopharmaceutical manufacturing…
Sharp Services Invests $100 Million in US & European Facilities to Increase Capacity & Service Offerings
Sharp Services, a leader in pharmaceutical packaging, clinical trial services & sterile manufacturing has announced a $100 million investment across its global facility network to…
Serán BioScience Expands Commercial Manufacturing With New Campus in Bend, Oregon
Serán BioScience, LLC, a leading science-driven drug development partner, today announced the completion of two of the three new buildings and commencement of construction of…
Orion & Abzena Announce Exclusive Commercial License for Abzena’s Antibody
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive focused commercial license to one of…
Aenova Expands Sterile Fill & Finish Manufacturing Capacity at its Latina Site
Latina (Italy), 23 October 2025 – Aenova, a leading global contract development and manufacturing organization (CDMO), announces a major investment in its sterile manufacturing capabilities…
Kindeva Announces the Appointment of David Stevens as President
Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, announced the promotion of David Stevens, Chief Operating and Commercial Officer, to…
Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases
Axial Therapeutics recently announced it has rebranded as Vertero Therapeutics, a biotechnology company breaking barriers in neurodegenerative disease treatment. The new identity reflects the Company's…
Simcha Therapeutics Presents Preclinical Data Demonstrating Potential for Decoy-Resistant IL-18 to Enhance Efficacy of Bi-specific T-cell Engagers
Simcha Therapeutics, a clinical-stage immunobiology company pioneering first-in-class cytokine treatments for cancer, today announced the presentation of preclinical results which demonstrate enhanced efficacy from combining…
Evonik Launches EUDRACAP Colon Functional Capsules in GMP Quality at CPHI Frankfurt
Evonik’s EUDRACAP colon functional capsules are now available produced under good manufacturing practice (GMP). Launched last year, EUDRACAP colon is the first functional, ready-to-fill capsule…
Roquette Returns to SupplySide Global With New, Unified Vision for Health & Nutrition
Roquette, a global leader in plant-based ingredients, will debut its newly expanded portfolio at SupplySide Global 2025. The event marks the company’s first presentation combining…
Hovione Completes Initial $100M Investment Cycle to Expand US Operations at New Jersey Manufacturing Campus
Hovione, a fully-integrated global CDMO, today announced the completion of an initial multi-million-dollar investment cycle to expand its manufacturing campus in East Windsor, New Jersey.…
XOMA Royalty & LAVA Therapeutics Announce Amendment to Purchase Agreement
XOMA Royalty Corporation and LAVA Therapeutics N.V. recently announced that they have reached an agreement to amend their previously announced definitive share purchase agreement .…
